A Randomized, Double-blind and Parallel Group Study to Compare the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Xgeva® in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases
- Focus Pharmacokinetics
- Sponsors Qilu Pharmaceutical
- 14 Oct 2019 Status changed from active, no longer recruiting to completed.
- 10 Apr 2019 Status changed from recruiting to active, no longer recruiting.
- 06 Sep 2018 New trial record